Tesofensine — Precision Weight Loss
Through Neuroscience
A triple monoamine reuptake inhibitor that targets the brain's appetite and reward pathways, delivering significant fat loss with once-daily oral dosing — no injections required.
Pharmaceutical-grade tesofensine, compounded by a U.S.-licensed pharmacy and prescribed by a licensed physician. Your consultation, cardiovascular monitoring protocol, and shipping are included.
Prescription required. Provider consultation, cardiovascular monitoring, and shipping included.
- Drug Class
- Triple Monoamine Reuptake Inhibitor
- Mechanism
- Serotonin + Norepinephrine + Dopamine Reuptake Inhibition
- Administration
- Once-daily oral capsule (morning dosing)
- Clinical Result
- 10.6% mean body weight reduction in 24 weeks (Astrup et al., 2008)
- Body Composition
- ~79% of weight lost was fat mass (Sjodin et al., 2010)
- Half-Life
- ~220 hours (~9 days) (Heal et al., 2013)
- Availability
- Licensed US compounding pharmacies (not FDA-approved)
What Is Tesofensine?
Tesofensine is a novel triple monoamine reuptake inhibitor originally developed by NeuroSearch A/S as a treatment for Parkinson's disease and Alzheimer's disease. During early clinical trials for those neurological conditions, researchers observed substantial and consistent weight loss among study participants — a finding significant enough to redirect the compound's development toward obesity treatment (Astrup et al., 2008).
The molecule works by inhibiting the reuptake of three key neurotransmitters: serotonin, norepinephrine, and dopamine. This triple mechanism is what distinguishes tesofensine from older weight-loss medications that typically target only one or two of these pathways. By modulating all three simultaneously, tesofensine addresses multiple dimensions of appetite regulation — from baseline hunger signaling to the reward-driven cravings that make sustained caloric restriction so difficult for many patients.
In Mexico, a combination product containing tesofensine and naltrexone has been approved under the brand name Obeclox. Tesofensine monotherapy is not currently FDA-approved in the United States but is available through licensed US compounding pharmacies under physician supervision from our medical team. Its long half-life of approximately 220 hours (~9 days) supports convenient once-daily oral dosing (Heal et al., 2013).
Important regulatory notice: Tesofensine has not completed Phase III clinical trials in the United States. Availability through compounding pharmacies does not constitute FDA approval or endorsement.
Note: Although tesofensine is often discussed alongside peptide therapies for weight loss, it is not a peptide. It is a small-molecule pharmaceutical compound with a distinct chemical structure and mechanism of action.
How Tesofensine Works
Tesofensine represents a fundamentally different approach to medical weight management. Rather than mimicking gut hormones like GLP-1 receptor agonists, it works at the neurological level — modulating three key neurotransmitter systems simultaneously.
Serotonin Reuptake Inhibition — Satiety Enhancement
Tesofensine blocks the reuptake of serotonin (5-HT) at synaptic junctions, increasing its availability in the central nervous system. Elevated serotonergic tone is directly linked to enhanced feelings of fullness after meals, reduced portion sizes, and decreased carbohydrate cravings (Heal et al., 2013).
Norepinephrine Reuptake Inhibition — Metabolic Activation
Of the three reuptake pathways, tesofensine shows its highest binding affinity for the norepinephrine transporter (NET). By sustaining elevated norepinephrine levels, tesofensine supports increased resting energy expenditure and enhanced fat oxidation (Heal et al., 2013).
Dopamine Reuptake Inhibition — Reward Pathway Modulation
Perhaps the most clinically meaningful differentiator is tesofensine's action on the dopamine transporter (DAT). By increasing dopaminergic tone, tesofensine helps normalize reward pathways, reducing compulsive and emotional eating behaviors (Astrup et al., 2008).
Sustained Action — Once-Daily Convenience
With a biological half-life of approximately 220 hours (~9 days), tesofensine achieves stable plasma concentrations with once-daily dosing. This means consistent appetite suppression throughout the day without peaks and troughs (Heal et al., 2013).
Key Benefits of Tesofensine
Significant Fat-Preferential Weight Loss
Phase II data demonstrated 10.6% mean body weight reduction at 0.5 mg over 24 weeks, with DEXA scans confirming ~79% of weight lost was fat mass (Astrup et al., 2008; Sjodin et al., 2010).
Meaningful Caloric Intake Reduction
Clinical trial participants showed ~26% reduction in ad libitum energy intake driven by genuine appetite reduction rather than willpower alone (Sjodin et al., 2010).
Oral Administration
Once-daily capsule taken in the morning. No injections, no refrigeration, no injection-site reactions.
Addresses Reward-Driven Eating
The dopaminergic component targets compulsive eating patterns, emotional eating, and food-focused rumination that other weight-loss medications do not adequately address.
Muscle-Sparing Profile
The high proportion of fat mass loss relative to total weight loss suggests favorable body composition outcomes compared to caloric restriction alone (Sjodin et al., 2010).
Convenient Once-Daily Dosing
The long half-life of ~220 hours supports reliable once-daily dosing with consistent appetite suppression across the full 24-hour cycle.
Who Is Tesofensine For?
Good candidates for tesofensine include patients who:
- Have a BMI of 30 or greater (obese), or a BMI of 27 or greater with at least one weight-related comorbidity
- Have not achieved adequate results with diet and exercise alone
- Prefer oral medication over injectable therapies such as semaglutide or tirzepatide
- Experience significant reward-driven eating, compulsive snacking, or emotional eating
- Have previously tried GLP-1 receptor agonists and experienced intolerable gastrointestinal side effects
- Are seeking a medication that specifically addresses the neurological drivers of overeating
Tesofensine is contraindicated in patients with:
- ✕Uncontrolled hypertension or significant cardiovascular disease
- ✕History of stroke or transient ischemic attack (TIA)
- ✕Narrow-angle glaucoma
- ✕Hyperthyroidism
- ✕Seizure disorders
- ✕Hepatic impairment
- ✕Pregnancy or breastfeeding
- ✕Current use of MAO inhibitors (must allow a 14-day washout period)
Drug interactions requiring disclosure: Patients must inform their prescribing physician if they are taking SSRIs, SNRIs, sympathomimetic medications, strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), or St. John's Wort.
Dosage & Administration
Dose
0.5 mg once daily
Form
Oral capsule
Timing
Morning, with or without food
Protocol
6-month treatment course (matches 24-week trial)
Cardiovascular Monitoring Protocol
Tesofensine requires cardiovascular monitoring due to dose-dependent increases in heart rate and blood pressure observed in clinical trials (~7.4 bpm increase at 0.5 mg) (Astrup et al., 2008).
| Timepoint | Monitoring |
|---|---|
| Baseline (before starting) | Blood pressure, resting heart rate, comprehensive metabolic panel |
| 2 weeks | Blood pressure, resting heart rate — assess tolerability |
| 4 weeks | Blood pressure, resting heart rate — confirm stable cardiovascular response |
| Quarterly (ongoing) | Blood pressure, resting heart rate, metabolic panel |
Discontinuation Criteria
Sustained resting heart rate above 100 bpm, systolic blood pressure above 160 mmHg, diastolic blood pressure above 100 mmHg, or any cardiovascular symptoms (chest pain, palpitations, syncope) warrant immediate discontinuation and medical evaluation.
Tesofensine Pricing at VitalRx
Tesofensine 0.5mg Capsules — 6-Month Clinical Protocol
Tesofensine 0.5mg Capsules
30 capsules/month • 1 capsule daily (morning dosing)
$149/month
$894 total for 6-month protocol
The 6-month protocol aligns with the 24-week duration of the Phase II clinical trial that demonstrated 10.6% mean body weight reduction (Astrup et al., 2008). Your prescribing physician will monitor your progress throughout the full treatment course.
How to Get Started with Tesofensine at VitalRx
Complete Your Health Profile
Fill out a brief online health questionnaire covering your medical history, current medications, weight-loss goals, and cardiovascular health. This takes about 5 minutes.
Physician Consultation
A licensed physician reviews your profile and conducts a telehealth consultation to determine whether tesofensine is appropriate for you, including cardiovascular risk assessment.
Prescription & Compounding
If prescribed, your tesofensine is compounded by a licensed US pharmacy and shipped directly to your door. No trips to a pharmacy required.
Ongoing Monitoring & Support
Your physician monitors your progress, manages your dosage, and conducts cardiovascular follow-ups according to the monitoring protocol.
Prescription required. Provider consultation included. Cardiovascular monitoring protocol included.
Tesofensine vs. GLP-1 Receptor Agonists
| Feature | Tesofensine | Semaglutide | Tirzepatide |
|---|---|---|---|
| Drug Class | Triple monoamine reuptake inhibitor | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Mechanism | Serotonin + norepinephrine + dopamine modulation | GLP-1 mimicry, gastric slowing | GLP-1 + GIP mimicry |
| Administration | Once-daily oral capsule | Once-weekly injection | Once-weekly injection |
| Addresses Reward Eating | Yes (dopaminergic pathway) | Limited | Limited |
| Refrigeration Required | No | Varies by formulation | Varies by formulation |
| GI Side Effects | Lower GI burden (most common: dry mouth) | Nausea, vomiting, diarrhea common | Nausea, vomiting, diarrhea common |
| FDA Status | Not FDA-approved | FDA-approved | FDA-approved |
| Phase II Weight Loss | 10.6% at 24 weeks (0.5 mg) | ~15% at 68 weeks (2.4 mg) | ~20% at 72 weeks (15 mg) |
Cross-trial comparison disclaimer: The weight-loss figures above come from separate clinical trials with different designs, durations, patient populations, and dietary protocols. Direct numerical comparisons should be interpreted with caution.
The choice between tesofensine and GLP-1 receptor agonists depends on your clinical profile, preferences, and treatment goals. GLP-1 agents like semaglutide and tirzepatide have a larger evidence base and FDA approval. Tesofensine offers a distinct neurological mechanism, oral dosing, and a differentiated approach to reward-driven eating. Your prescribing physician can help determine the best approach for your situation.
How to Buy Tesofensine Online
Tesofensine is available through VitalRx with a valid prescription from a licensed physician. Because tesofensine is not FDA-approved, it is compounded by licensed US pharmacies specifically for your prescription. You cannot purchase tesofensine over the counter or without a medical evaluation.
- Start your evaluation by completing a health profile
- Consult with a licensed physician who will assess your candidacy
- If prescribed, your tesofensine capsules are compounded and shipped to you
The entire process — from evaluation to delivery — typically takes 5-7 business days. All consultations are conducted via telehealth for your convenience.
Frequently Asked Questions About Tesofensine
The information provided on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Tesofensine has not completed Phase III clinical trials in the United States and is not approved by the U.S. Food and Drug Administration (FDA). Availability through licensed compounding pharmacies does not constitute FDA approval or endorsement. All medications prescribed through VitalRx require a consultation with a licensed physician who will determine appropriateness based on your individual health profile. Results discussed on this page are based on Phase II clinical trial data and may not be representative of individual outcomes. Common side effects include dry mouth, insomnia, nausea, constipation, and dose-dependent increases in heart rate and blood pressure. Tesofensine should only be taken under direct medical supervision with appropriate cardiovascular monitoring. Do not start, stop, or change any medication without consulting your healthcare provider. If you experience chest pain, rapid heartbeat, severe headache, or other concerning symptoms, seek immediate medical attention.